Promotion of indigenous pharmaceutical manufacturing

PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore

US & UK reach historic pharma pricing pact

The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic

LENZ Therapeutics, Lotus Pharmaceutical submit NDA for presbyopia treatment in Korea

Presbyopia, the age-related loss of near vision, could soon be treated successfully

Sun Pharma introduces Ilumya in India for treatment of plaque psoriasis

Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials

Sudapack breaks ground on major PharmaGuard expansion in Erolzheim

Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production

SK Biopharmaceuticals acquires exclusive global rights for WARF cancer drug candidate

SAI Parenteral's acquires Australia's Noumed Pharmaceuticals for Rs. 125 Cr

Gan & Lee Pharma launches Phase 3 trial of once-monthly weight-loss jab

InnoCare Pharma launches global Phase II trial of TYK2 inhibitor for prurigo nodularis in China

Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders

Ascendis Pharma’s FDA review of Achondroplasia drug gets 3-month delay

The FDA has classified recent submissions as a major amendment pushing the approval to its NDA for TransCon CNP back three months to February 28, 2026